BeiGene, Ltd. 06160 2022 3 31 13.09 571 XIVA 2022 3 31 2022 3 31 2022 2022 2023 2022 5 5 1 1995 (Private Securities Litigation Reform Act of 1995) 10-K 2022 5 5 Anthony C. Hooper Margaret Han Dugan Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders 2 2022 2022 2.616 1.061 146% 2022 372% ALPINE FDA EMA RATIONALE306 2022 5 5 BGNE 06160 688235 2022 (John V. Oyler) 3 ALPINE RATIONALE306 3 2022 2022 3 31 63 2021 12 31 66 2022 3 31 2.366 4.343 1.221 7,560 4,510 1,130 2022 3 31 3.066 2021 6.059 2022 3 31 2.616 2021 1.061 2022 1.043 2,210 2022 8,760 4,890 2022 2,990 1,450 2021 8 2022 1 2022 2,720 2,030 2022 3 31 4,510 2021 6.5 2021 3 2021 3 31 4.998 4 2022 3 31 7.499 2021 5.357 2022 3 31 6,520 2021 3,270 2021 8 2022 3 31 3.899 2021 3.207 CRO 2022 2021 0 850 2022 3 31 3,090 2021 2,190 (SG&A) 2022 3 31 SG&A 2.946 2021 SG&A 1.821 SG&A SG&A SG&A 2022 2021 SG&A 3,470 2,390 2022 3 31 4.343 6,650 2022 3 31 0.33 (ADS) 4.24 2021 3 31 0.06 0.05 ADS 0.73 0.69 5 2022 146% 2022 1.043 372% 6,790 570% (MCL) (WM) (MZL) 3,350 180% (CLL) 2022 8,760 79% (NRDL) 5 BTK (BTK) 47 25 4,000 3 ALPINE(NCT03734016) (IRC) (R/R) (CLL) (SLL) 6 3 (NCT05100862) R/R MZL IgG4 PD-1 Fc γ 8 35 9,000 (MSI-H) (dMMR) (ESCC) (EMA) ESCC (NSCLC) NSCLC NSCLC EGFR ALK NSCLC ESCC 3 RATIONALE306(NCT03783442) (OS) 2022 (ASCO) (NPC) 3 RATIONALE309(NCT03924986) 2022 ASCO (AACR)2022 NSCLC 3 RATIONALE303(NCT03358875) RATIONALE304(NCT03663205) PD-L1>5% (G/GEJ) 3 RATIONALE305(NCT03777657) 7 (BGB-A1217) Fc TIGIT 25 1,000 o BGB-A445 OX40 o BGB-15025 1(HPK1) o BGB-10188 PI3Kδ o BGB-23339 2(TYK2) BGB-16673 BTK CDAC B 1 BLINCYTO (R/R)CD19 B (ALL) 8 Zymeworks Z y m e w o r k s HERIZON-BTC-01(NCT04466891) Zanidatamab HER2 (BTC) III IV 2022 100 9.3 5.2 6 2023 10 8,000 2022 GMP 64,000 (Ernst & Young LLP) 2022 12 31 9 2021 (ESG) ESG 2022 ASCO R/R 2 ROSEWOOD (NCT03332017) WM 3 ASPEN (NCT03053440) FDA CLL/SLL (PDUFA) FDA 2022 10 22 EMA CLL MZL 2022 3 ALPINE(NCT03734016) 2022 (NMPA) (NPC) EMA NSCLC ESCC (MAA) 2022 NPC NSCLC 10 FDA ESCC (BLA) PDUFA FDA 2022 7 12 2022 (HCC) 3 (NCT03412773) (Ociperlimab) 2022 2022 1 (NCT04047862) 2022 3 (NCT03519230) BGB-11417 BCL-2 2022 2022 (NHL) CLL 1 NCT04277637 NCT04771130 2022 1 2022 BGB-A445(OX-40) 1 (NCT04215978) 2022 HPK1 BGB-15025 2022 LBL-007 surzebiclimab(TIM3) LBL-007 LAG-3 11 Zanidatamab Zymeworks 2023 HERIZON-BTC-01(NCT04466891) 12 1,000 2022 2021 3 31 12 31 $ 6,252,233 $ 6,624,849 190,800 483,113 624,673 587,605 8,021,388 8,645,949 236,915 262,400 385,976 558,055 368,027 407,703 368,543 390,362 608,992 629,678 2,135,888 2,402,962 $ 5,885,500 $ 6,242,987 13 ADS ADS 1,000 3 31 3 2022 2021 $ 261,573 $ 106,117 45,053 499,755 306,626 605,872 65,237 32,685 389,915 320,726 294,573 182,106 188 188 749,913 535,705 (443,287) 70,167 10,071 (4,179) 11,967 (4,123) (421,249) 61,865 13,025 (4,630) (434,274) 66,495 $ (0.33) $ 0.06 $ (0.33) $ 0.05 1,332,017,262 1,188,943,726 1,332,017,262 1,257,489,671 ADS $ (4.24) $ 0.73 $ (4.24) $ 0.69 ADS 102,462,866 91,457,210 102,462,866 96,729,975 14 40 2030 20 8,000 www.beigene.com.cn 1995 (Private Securities Litigation Reform Act of 1995) 10-K (+86 10)5895-8058 (+86 10)6844-5311 ir@beigene.com media@beigene.com 15 16